A citation-based method for searching scientific literature

Emma G Wilmot, Pratik Choudhary, Lalantha Leelarathna, Mike Baxter. Diabetes Obes Metab 2019
Times Cited: 9







List of co-cited articles
29 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes.
Thomas Danne, Jeremy Pettus, Andrea Giaccari, Bertrand Cariou, Helena Rodbard, Stuart A Weinzimer, Mireille Bonnemaire, Sangeeta Sawhney, John Stewart, Stella Wang,[...]. Diabetes Technol Ther 2019
6
16

SGLT-2 Inhibitors and GLP-1 Agonists: First-Line Therapy for Diabetes With Established Cardiovascular Disease.
Aparna P Sajja, Amit K Dey, Avirup Guha, Youssef Elnabawi, Aditya A Joshi, Ankur Kalra. J Cardiovasc Pharmacol Ther 2019
6
16


Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program.
David R Matthews, Qiang Li, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Mehul Desai, William R Hiatt, Mark Nehler, Elisa Fabbrini,[...]. Diabetologia 2019
41
11

Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes.
Bruce A Perkins, Julio Rosenstock, Jay S Skyler, Lori M Laffel, David Z Cherney, Chantal Mathieu, Christianne Pang, Richard Wood, Ona Kinduryte, Jyothis T George,[...]. Diabetes Care 2019
3
33

The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes.
Daniël H van Raalte, Petter Bjornstad, Frederik Persson, David R Powell, Rita de Cassia Castro, Ping Stella Wang, Minzhi Liu, Hiddo J L Heerspink, David Cherney. Diabetes Care 2019
10
11


Type 1 diabetes mellitus.
Anastasia Katsarou, Soffia Gudbjörnsdottir, Araz Rawshani, Dana Dabelea, Ezio Bonifacio, Barbara J Anderson, Laura M Jacobsen, Desmond A Schatz, Åke Lernmark. Nat Rev Dis Primers 2017
232
11

Improvement in Patient-Reported Outcomes in Adults with Type 1 Diabetes Treated with Sotagliflozin plus Insulin Versus Insulin Alone.
Thomas Danne, Vijay N Joish, Marion Afonso, Phillip Banks, Sangeeta Sawhney, Pablo Lapuerta, Michael J Davies, John B Buse, Dee Lin, Matthew Reaney,[...]. Diabetes Technol Ther 2021
1
100


Dose-dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial.
Claire Baker, Suman Wason, Phillip Banks, Sangeeta Sawhney, Anna Chang, Thomas Danne, Diane Gesty-Palmer, Jake A Kushner, Darren K McGuire, Frank Mikell,[...]. Diabetes Obes Metab 2019
9
11

Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program.
Thomas Danne, Bertrand Cariou, John B Buse, Satish K Garg, Julio Rosenstock, Phillip Banks, Jake A Kushner, Darren K McGuire, Anne L Peters, Sangeeta Sawhney,[...]. Diabetes Care 2019
27
11

Hyperglycemic crises in adult patients with diabetes.
Abbas E Kitabchi, Guillermo E Umpierrez, John M Miles, Joseph N Fisher. Diabetes Care 2009
661
11

Adjunct Therapy in Type 1 Diabetes: A Survey to Uncover Unmet Needs and Patient Preferences Beyond HbA1c Measures.
Jeremy H Pettus, Jake A Kushner, Virginia Valentine, Richard Wood, Christianne Pang, Sachin Paranjape, Rachele Berria, Antonio Deluzio, Steven E Edelman. Diabetes Technol Ther 2019
3
33

Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives.
Chiara Maria Assunta Cefalo, Francesca Cinti, Simona Moffa, Flavia Impronta, Gian Pio Sorice, Teresa Mezza, Alfredo Pontecorvi, Andrea Giaccari. Cardiovasc Diabetol 2019
30
11

Glycaemic control of Type 1 diabetes in clinical practice early in the 21st century: an international comparison.
J A McKnight, S H Wild, M J E Lamb, M N Cooper, T W Jones, E A Davis, S Hofer, M Fritsch, E Schober, J Svensson,[...]. Diabet Med 2015
160
11

LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.
B Zambrowicz, J Freiman, P M Brown, K S Frazier, A Turnage, J Bronner, D Ruff, M Shadoan, P Banks, F Mseeh,[...]. Clin Pharmacol Ther 2012
149
11

Insights Into Patients' Experience With Type 1 Diabetes: Exit Interviews From Phase III Studies of Sotagliflozin.
Claire Ervin, Vijay N Joish, Emily Evans, Dana DiBenedetti, Matthew Reaney, Ronald Preblick, Rita Castro, Thomas Danne, John B Buse, Pablo Lapuerta. Clin Ther 2019
2
50

International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors.
Thomas Danne, Satish Garg, Anne L Peters, John B Buse, Chantal Mathieu, Jeremy H Pettus, Charles M Alexander, Tadej Battelino, F Javier Ampudia-Blasco, Bruce W Bode,[...]. Diabetes Care 2019
89
11


Utilizing the Ambulatory Glucose Profile to Standardize and Implement Continuous Glucose Monitoring in Clinical Practice.
Mary L Johnson, Thomas W Martens, Amy B Criego, Anders L Carlson, Gregg D Simonson, Richard M Bergenstal. Diabetes Technol Ther 2019
18
11

Association between Inflammation and Biological Variation in Hemoglobin A1c in U.S. Nondiabetic Adults.
Shuqian Liu, James M Hempe, Robert J McCarter, Shengxu Li, Vivian A Fonseca. J Clin Endocrinol Metab 2015
27
11

Translating the A1C assay into estimated average glucose values.
David M Nathan, Judith Kuenen, Rikke Borg, Hui Zheng, David Schoenfeld, Robert J Heine. Diabetes Care 2008
789
11

Association of glycation gap with mortality and vascular complications in diabetes.
Ananth U Nayak, Alan M Nevill, Paul Bassett, Baldev M Singh. Diabetes Care 2013
26
11

The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial.
James M Hempe, Shuqian Liu, Leann Myers, Robert J McCarter, John B Buse, Vivian Fonseca. Diabetes Care 2015
76
11

Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring.
Dongyuan Xing, Craig Kollman, Roy W Beck, William V Tamborlane, Lori Laffel, Bruce A Buckingham, Darrell M Wilson, Stuart Weinzimer, Rosanna Fiallo-Scharer, Katrina J Ruedy. Diabetes Technol Ther 2011
45
11


High and low hemoglobin glycation phenotypes in type 1 diabetes: a challenge for interpretation of glycemic control.
James M Hempe, Ricardo Gomez, Robert J McCarter, Stuart A Chalew. J Diabetes Complications 2002
149
11


Progression of nephropathy in type 2 diabetes: the glycation gap is a significant predictor after adjustment for glycohemoglobin (Hb A1c).
Santiago Rodríguez-Segade, Javier Rodríguez, Jose M Cabezas-Agricola, Felipe F Casanueva, Félix Camiña. Clin Chem 2011
30
11

Continuous Glucose Monitoring: Review of an Innovation in Diabetes Management.
Zainab Mian, Kathie L Hermayer, Alicia Jenkins. Am J Med Sci 2019
13
11

Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring.
Richard M Bergenstal, Roy W Beck, Kelly L Close, George Grunberger, David B Sacks, Aaron Kowalski, Adam S Brown, Lutz Heinemann, Grazia Aleppo, Donna B Ryan,[...]. Diabetes Care 2018
110
11



Does glucose variability influence the relationship between mean plasma glucose and HbA1c levels in type 1 and type 2 diabetic patients?
Judith C Kuenen, Rikke Borg, Dirk J Kuik, Hui Zheng, David Schoenfeld, Michaela Diamant, David M Nathan, Robert J Heine. Diabetes Care 2011
41
11

Glucose Management Indicator (GMI): Insights and Validation Using Guardian 3 and Navigator 2 Sensor Data.
Lalantha Leelarathna, Roy W Beck, Richard M Bergenstal, Hood Thabit, Roman Hovorka. Diabetes Care 2019
6
16

Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes.
Robert J McCarter, James M Hempe, Ricardo Gomez, Stuart A Chalew. Diabetes Care 2004
127
11


Optimal Sampling Duration for Continuous Glucose Monitoring to Determine Long-Term Glycemic Control.
Tonya D Riddlesworth, Roy W Beck, Robin L Gal, Crystal G Connor, Richard M Bergenstal, Sooji Lee, Steven M Willi. Diabetes Technol Ther 2018
64
11

GlyCulator2: an update on a web application for calculation of glycemic variability indices.
Konrad Pagacz, Konrad Stawiski, Agnieszka Szadkowska, Wojciech Mlynarski, Wojciech Fendler. Acta Diabetol 2018
8
12


Flash glucose monitoring improves glycemia in higher risk patients: a longitudinal, observational study under real-life settings.
Sujit Jangam, Timothy Dunn, Yongjin Xu, Gary Hayter, Ramzi A Ajjan. BMJ Open Diabetes Res Care 2019
8
12


Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups.
Nathan R Hill, Nick S Oliver, Pratik Choudhary, Jonathan C Levy, Peter Hindmarsh, David R Matthews. Diabetes Technol Ther 2011
155
11


The application of simple metrics in the assessment of glycaemic variability.
L Monnier, C Colette, D R Owens. Diabetes Metab 2018
34
11

Glycemic Variability Percentage: A Novel Method for Assessing Glycemic Variability from Continuous Glucose Monitor Data.
Thomas A Peyser, Andrew K Balo, Bruce A Buckingham, Irl B Hirsch, Arturo Garcia. Diabetes Technol Ther 2018
24
11

Understanding meal patterns: definitions, methodology and impact on nutrient intake and diet quality.
Rebecca M Leech, Anthony Worsley, Anna Timperio, Sarah A McNaughton. Nutr Res Rev 2015
123
11



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.